Home Blog Page 1514

Leading South Korean Printer TARAtps Acquires Chicago Offset, Establishes TARA USA

By
Advertorial Desk
-

With the US printing firm now a wholly owned subsidiary of TARAtps, the newly established TARA USA is set to strengthen value for North American customers with a dual-production system spanning South Korea and the US.

CHICAGO, Dec. 11, 2025 /PRNewswire/ — TARAtps, one of South Korea’s largest and most comprehensive printing companies, today announced the full acquisition of the Illinois-based commercial printing firm Chicago Offset, which will now operate as a wholly owned subsidiary. TARAtps is concurrently announcing the establishment of TARA USA, its first overseas corporate entity, to expand and coordinate operations across the North American market.

TARAtps and Chicago offset SPA signing ceremony(Joe Kim and Hoyeon Kang from left)
TARAtps and Chicago offset SPA signing ceremony(Joe Kim and Hoyeon Kang from left)

Recognized for its sheet-fed printing presses, saddle-stitching lines, and long-standing commercial printing capabilities, Chicago Offset will retain its established brand identity while integrating into TARAtps’ global manufacturing network. The strategic move strengthens TARAtps’ ability to support customers throughout the United States and the broader North and Central American region.

“This acquisition provides a critical foothold for TARAtps in North America,” said Wonjae Jang, Director of the International Business Division at TARAtps. “By combining the mass-production capacity of our Paju headquarters with the agility of US-based manufacturing, we are building a dual-production system that dramatically shortens lead times and strengthens our ability to respond to both large-volume and short-run orders.”

Dual-production system for faster, more agile delivery

The newly established TARA USA will serve as TARAtps’ operational hub in the United States, overseeing customer engagement, project coordination, and integrated production management across nearby regions. Through the alignment of Korea-based large-scale production capabilities with the on-site responsiveness of Chicago Offset, TARAtps is implementing a nearshore-optimized supply chain tailored to North American clients.

This dual-production framework is designed to reduce turnaround times, improve cost efficiency, and deliver greater supply chain flexibility for publishers, corporate clients, and K-content partners. The unified system strengthens TARAtps’ global competitiveness and enhances its ability to support a wide range of print demands — from high-volume national publishing projects to fast-response regional orders.

“North America has always been one of our most important markets,” Jang added. “By supporting US publishers and corporate customers directly within the country, we can provide greater value, tighter delivery windows, and a truly global standard of print service.”

About TARAtps

TARAtps is South Korea’s leading comprehensive printing company, serving global clients across publishing, commercial printing, packaging, and K-pop merchandise and album packaging production. With more than 30 years of continuous growth, TARAtps is known for its advanced manufacturing platforms, color-management expertise, eco-certified operations, and large-scale production capabilities based in Paju, South Korea. The company provides end-to-end solutions for books, textbooks, stationery, diaries, merchandise, and premium custom print products.

www.taratps.com

 

SINBON Expansion as Green Solutions Provider Aimed at Transforming Electronics into Conduits of Sustainability

By
Advertorial Desk
-

TAIPEI, Dec. 11, 2025 /PRNewswire/ — SINBON Electronics Co., Ltd. (TWSE#:3023) today announced a strategic expansion of its role as a sustainable solutions provider, leveraging its core strengths in customized electronics to help customers across industries achieve environmental goals. The company is building a broader platform to transform electronics solutions into conduits of sustainability, supported by its global footprint and expertise in e-mobility, renewable energy, and industrial efficiency.

“Sustainability has always been at the core of what SINBON does, so this evolution is the natural next step,” commented Lily Huang, Chief Sustainability Officer at SINBON Electronics. “By expanding our focus as a green solutions provider, we’re helping customers turn environmental responsibility into a competitive advantage. Our expertise in green industries and commitment to sustainability as a company position SINBON to lead this transformation.”

Sustainable solutions across industries

In addition to ensuring customer success, SINBON’s solutions are designed around sustainability, helping customers to reduce environmental impact while delivering operational efficiency. Across verticals, the company’s impact includes:

  • E-mobility: SINBON is building an ecosystem across smart transportation and e-mobility, spanning electric vehicle (EV) charging infrastructure to custom-built e-bike fleets. A key collaboration has been its ongoing partnership with the German battery swapping startup Swobbee. The companies are working together to advance battery-as-a-service models for light EVs and e-bikes, aimed at disrupting and democratizing urban last-mile delivery across Europe and the US.
  • Humanoid robotics: By increasing efficiency, robots have the potential to improve the sustainability of operations across a wide range of industries by optimizing energy use and minimizing waste. Having recently entered the market for humanoid robots, SINBON has established a partnership with TURVO International Co., Ltd., a specialist in precision metal components, gearbox reducers, and quality control. The collaboration is aimed at jointly deploying advanced robotics solutions to broaden possibilities for applications and elevate service capabilities.
  • Renewable energy supply chain: SINBON provides comprehensive connectivity solutions for the renewable energy sector, including solar photovoltaic panel makers, wind power equipment manufacturers, and energy storage system providers. With its focus on reducing its own environmental impact, the company continues to support the carbon reduction efforts downstream of these customers.
  • Increasing energy efficiency of global industrial sectors: The company’s solutions are designed from the beginning to maximize energy efficiency and come with reliable evaluations of carbon footprint contribution. For customers in the carbon-intensive industrial sectors, this means reducing costs along with environmental impact, as well as building transparency into each solution.

Sustainable practices as a company

SINBON has been integrating the same sustainability principles into its own operations. The company has made significant progress, and key highlights from its most recent Sustainability Report include:

  • Emissions: By 2024, SINBON reduced Scope 1 and Scope 2 emissions by 28.8% compared to 2021 levels as a baseline.
  • Renewable energy: By 2024, the company’s usage of renewable energy reached 2,682,743 kWh, and its self-owned solar energy capacity reached 3 MW.

Regional facilities bring operations closer to customers

Along with an existing facility in Hungary, this year SINBON invested in US manufacturing with a newly expanded facility in Ohio. With dedicated sites in North America and Europe, the company brings production closer to customers, reducing emissions associated with shipping and transportation while facilitating collaboration.

About SINBON

Established in 1989, SINBON empowers industries through intelligent connectivity and sustainable innovation—enabling cleaner mobility, ethical automation, and renewable energy, while advancing technology with purpose and care for the planet.

Our commitment to ESG drives this mission. We continually strengthen carbon management and pursue sustainable innovation, working hand in hand with our partners to spark positive cycles, generate diverse value, and deliver trusted green solutions with lasting impact.

With a presence across Asia, Europe, and the Americas, our global team shares a common mission: to make innovation inseparable from sustainability, and progress inseparable from care.

For more information: https://www.sinbon.com/

https://www.linkedin.com/company/sinbon-electronics/

Media contact

Penny Huang
Email: pr@sinbon.com 

Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000

By
Advertorial Desk
-
Calgary, Alberta – Newsfile Corp. – December 10, 2025 – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”), the leading autologous (patient’s own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, with ACP-01 at Doctors Hospital, Nassau, The Bahamas, is pleased to announce two major corporate developments:

  1. The U.S. Food and Drug Administration (FDA) has scheduled Hemostemix’s basket protocol Pre-IND meeting for January 16, 2026; and
  2. Subject to TSXV approval, the Company announces a non-brokered private placement of up to $960,000.

FDA Schedules Hemostemix Basket Protocol Pre-IND Meeting

The FDA has scheduled Hemostemix’s Pre-IND meeting for January 16, 2026 to review the Company’s basket clinical trial protocol for the treatment of ischemia, including:

  • Vascular dementia
  • Ischemic cardiomyopathy
  • Peripheral arterial disease (PAD)
  • Generalized ischemia

The basket protocol unifies these conditions under a single ischemia-based mechanism of action for ACP-01. Hemostemix will present its clinical rationale, manufacturing platform, and regulatory pathway, to advance toward FDA clearance of its Phase I basket clinical trial of ACP-01.

Non-Brokered Private Placement (NBPP)

The Company announces a non-brokered private placement of up to $960,000, consisting of the issuance of 8,000,000 common shares at a price of $0.12 per share, with no warrants.

All securities issued will be subject to a four-month hold period in accordance with applicable securities laws and TSX Venture Exchange (“TSXV”) policies. The financing is subject to final TSXV approval.

CEO Comment

“The FDA Pre-IND meeting brings us closer to a unified ischemia-based clinical trial program,” stated Thomas Smeenk, CEO. “It makes sense to address ischemia in multiple indications, given our success rate in these conditions as published in 11 peer reviewed articles. Why a Phase I clinical trial? First, Lantrida, an allogenic stem cell treatment, was approved on phase I only data. That is a precedent. Second, we can charge patients to be studied (treated) and followed. Third, we can publish the interim results and end points, comparing improvements in cognition (vascular dementia), LVEF% (ICM), wound healing (PAD), reduction of pain (general ischemia, ICM + PAD), and improvement in quality of life (all indications) for all participants. Plus, it generates a protocol for all patients who are treated, who do not meet inclusion criteria. Thus we study every patient treated with ACP-01 to generate the scientific basis for its approval,” Smeenk said.

Use of Proceeds

Proceeds will be used to advance:

  • FDA regulatory preparations and meeting execution
  • Clinical operations expansion in Florida, The Bahamas and Canada
  • General corporate working capital

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient’s own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO EM: tsmeenk@hemostemix.com / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Phase I basket protocol clinical trial of ACP-01 as a treatment for multiple indications of ischemia including Vascular Dementia, and the treatment of pain in Florida related related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia with Angiogenic Cell Precursors (ACP-01) in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix’s current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the “Litigation”); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix’s services and products; competition and Hemostemix’s competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix’s operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix’s markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix’s ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix’s disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

The issuer is solely responsible for the content of this announcement.

IKIGAI Corporation Opens New Vietnam Headquarters, Advancing a Vision for Global Harmony and a Better World

By
Advertorial Desk
-

HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 10 December 2025 – IKIGAI Corporation, a Japan-originated multi-sector enterprise, today announced the opening of its new headquarters at 87–97 Bach Dang, Tan Son Hoa, Ho Chi Minh City, marking a major milestone in its expansion into Vietnam and underscoring its long-term commitment to responsible, sustainable, and globally minded growth.

IKIGAI Corporation Opens New Vietnam Headquarters, Advancing a Vision for Global Harmony and a Better World
IKIGAI Corporation Opens New Vietnam Headquarters, Advancing a Vision for Global Harmony and a Better World

The headquarters will serve as IKIGAI’s regional hub across six strategic pillars: investment banking, fintech and digital banking, technology and deep-tech development, real estate and hospitality, agriculture and trade, and Japan–Vietnam talent mobility. The expansion further strengthens economic and cultural ties between Japan and Vietnam while supporting Vietnam’s modernization and digital transformation efforts.

“Vietnam is one of Asia’s most dynamic and promising markets,” said Mr. Toshihiro Soda, CEO of IKIGAI Corporation. “With our new headquarters in Ho Chi Minh City, we reaffirm our commitment to long-term value creation, cross-border collaboration, and bringing Japanese quality with compliance discipline, innovation, and sustainability principles to Vietnam.”

IKIGAI embraces a leadership philosophy that views business as a force for positive global impact. The corporation is dedicated to growth that enhances societal well-being, environmental resilience, technological advancement, and cross-border harmony—reflecting its belief in building value that uplifts communities and contributes to a more sustainable, equitable, and compassionate world.

Grounded in the IKIGAI Philosophy and guided by its cultural DNA, the corporation’s governance is anchored in eight core values: Goodness, Diligence, Integrity, Wisdom, Resilience, Compassion, Gratitude, and Harmony

These principles shape IKIGAI’s human-centered, ethical, and future-oriented development, and inspire the corporation’s mission to contribute meaningfully to a better world.
Hashtag: #IKIGAI

The issuer is solely responsible for the content of this announcement.

DNV RECEIVES CMS APPROVAL FOR NEW AMBULATORY SURGERY CENTERS ACCREDITATION PROGRAM

By
Advertorial Desk
-

New offering builds on DNV’s value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes

HOUSTON, Dec. 10, 2025 /PRNewswire/ — DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector. The new NIAHO® ASC Accreditation Program today received official approval from the US Centers for Medicare and Medicaid Services (CMS).

Ambulatory surgery centers, also known as outpatient or day surgery clinics, are among the fastest-growing segments in global healthcare. They offer a wide range of outpatient procedures and help reduce the burden on hospital systems by managing routine surgical interventions. Many ASCs focus on specific surgical specialties, while others provide multi-specialty services. In addition to delivering streamlined and cost-effective care, ASCs offer patients shorter wait times, faster scheduling, and a reduced risk of healthcare-associated infections. For many procedures, this model improves access to care and helps alleviate the growing demand for hospital beds.

Although ASCs are fiercely competitive in how they complement a healthcare system, much like any other healthcare organization they must uphold the highest standards of patient care and safety. This demands a tailored framework that differs from that of traditional hospitals, to meet a unique set of regulatory requirements.

Healthcare accreditation is a critical marker of quality that helps distinguish an ASC, which signals to the public an elite level of care they can expect. By pursuing ASC accreditation with DNV, centers that aim to enhance their competitiveness, scale rapidly, or achieve comprehensive quality assurance can maintain momentum in this dynamic sector.

DNV has been active in the U.S. healthcare market since 2008 and is now the fastest growing accrediting body for acute care, critical access, and psychiatric hospitals. Its uniquely collaborative model emphasizes operational alignment, year-round readiness, and staff development. Unlike traditional episodic inspections, DNV’s model provides three-year accreditation based on annual quality-of-care surveys. These collaborative assessments help staff understand what works, why it works, and how to drive continuous improvement.

The CMS approval (“deeming authority”) recognizes DNV as a nationally approved accreditation organization (AO) for ASCs. It allows DNV-accredited ASCs to be fully recognized for participation in federal benefit programs like Medicare and Medicaid, and by private health plans and commercial carriers who recognize CMS approval of accreditation organizations.

“Ambulatory surgery centers are transforming healthcare delivery not just in the United States, but around the world,” said Geir Fuglerud, CEO – Supply Chain & Product Assurance at DNV. “As demand for accessible, efficient, and high-quality surgical care continues to rise globally, ASCs are playing a vital role in relieving pressure on hospital systems and expanding patient access. Our value-driven accreditation model is specifically designed to support this evolution. It helps ASCs everywhere deliver safer patient care, improve medical outcomes and meet the expectations of modern healthcare systems.”

“Our NIAHO® accreditation has been a real success in hospitals of all sizes and kinds, creating a more empathetic and value-driven accreditation model in healthcare. We are proud to bring that same spirit of cooperation and continuous improvement to the ASC domain. The recognition from CMS underlines the program’s ability to help ASCs deliver excellence in operation and patient care,” added Alex Imperial, VP & Regional Manager, Supply Chain and Product Assurance Americas at DNV.

DNV’s ASC accreditation is highly scalable and adaptable. It recognizes the diversity of patient populations and ASC models, including those participating in Medicare or Medicaid, those reimbursed by private insurance, and those operating on a cash-pay basis. The program is supported by a range of standards, including ISO 9001, and is complemented by DNV’s specialty-focused Center of Excellence certifications.

Looking ahead, ASCs can also benefit from DNV’s full suite of specialized certifications and training programs. These include areas such as orthopedic and spine care, infection prevention in instrument management and sterile processing, and more.

DNV remains a trusted accreditor for healthcare organizations seeking to adapt to emerging trends, meet evolving regulatory demands, and deliver high-quality care across all areas of the healthcare system.

For more information about our ASC accreditation, visit our website  

 

DNV LAUNCHES ACCREDITATION FOR AMBULATORY SURGERY CENTERS

By
Advertorial Desk
-

New offering builds on DNV’s value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes

HOUSTON, Dec. 10, 2025 /PRNewswire/ — DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector.

Ambulatory surgery centers, also known as outpatient or day surgery clinics, are among the fastest-growing segments in global healthcare. They offer a wide range of outpatient procedures and help reduce the burden on hospital systems by managing routine surgical interventions. Many ASCs focus on specific surgical specialties, while others provide multi-specialty services. In addition to delivering streamlined and cost-effective care, ASCs offer patients shorter wait times, faster scheduling, and a reduced risk of healthcare-associated infections. For many procedures, this model improves access to care and helps alleviate the growing demand for hospital beds.

Although ASCs are fiercely competitive in how they complement a healthcare system, much like any other healthcare organization they must uphold the highest standards of patient care and safety. This demands a tailored framework that differs from that of traditional hospitals, to meet a unique set of regulatory requirements.

Healthcare accreditation is a critical marker of quality that helps distinguish an ASC, which signals to the public an elite level of care they can expect. By pursuing ASC accreditation with DNV, centers that aim to enhance their competitiveness, scale rapidly, or achieve comprehensive quality assurance can maintain momentum in this dynamic sector.

DNV has been active in the U.S. healthcare market since 2008 and is now the fastest growing and second largest accrediting body for acute care, critical access, psychiatric, and behavioral health hospitals. Its uniquely collaborative model emphasizes operational alignment, year-round readiness, and staff development. Unlike traditional episodic inspections, DNV’s model provides three-year accreditation based on annual quality-of-care surveys. These collaborative assessments help staff understand what works, why it works, and how to drive continuous improvement.

“Ambulatory surgery centers are transforming healthcare delivery not just in the United States, but around the world,” said Geir Fuglerud, CEO – Supply Chain & Product Assurance at DNV. “As demand for accessible, efficient, and high-quality surgical care continues to rise globally, ASCs are playing a vital role in relieving pressure on hospital systems and expanding patient access. Our value-driven accreditation model is specifically designed to support this evolution. It helps ASCs everywhere deliver safer patient care, improve medical outcomes and meet the expectations of modern healthcare systems.”

“Our NIAHO® accreditation has been a real success in hospitals of all sizes and kinds, creating a more empathetic and value-driven accreditation model in healthcare. We are proud to bring that same spirit of cooperation and continuous improvement to the ASC domain,” added Alex Imperial, VP & Regional Manager, Supply Chain and Product Assurance Americas at DNV.

DNV’s ASC accreditation is highly scalable and adaptable. It recognizes the diversity of patient populations and ASC models, including those participating in Medicare or Medicaid, those reimbursed by private insurance, and those operating on a cash-pay basis. The program is supported by a range of standards, including ISO 9001, and is complemented by DNV’s specialty-focused Center of Excellence certifications.

Looking ahead, ASCs can also benefit from DNV’s full suite of specialized certifications and training programs. These include areas such as orthopedic and spine care, infection prevention in instrument management and sterile processing, and more.

DNV remains a trusted accreditor for healthcare organizations seeking to adapt to emerging trends, meet evolving regulatory demands, and deliver high-quality care across all areas of the healthcare system.

For more information about our ASC accreditation, visit our website  

 

Bybit, Mantle, and Almanak Partner to Bring AI-Powered Quant Strategies Onchain at Global Scale

By
Advertorial Desk
-

DUBAI, UAE, Dec. 10, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, and Mantle, the high-performance distribution and liquidity layer for next-generation DeFi and real-world assets, today announced a strategic partnership with Almanak, the AI-powered quant platform enabling automated hedge-fund–grade strategies through a no-code, multi-agent AI system.

Bybit, Mantle, and Almanak Partner to Bring AI-Powered Quant Strategies Onchain at Global Scale
Bybit, Mantle, and Almanak Partner to Bring AI-Powered Quant Strategies Onchain at Global Scale

Following Almanak’s spot listing on Bybit, the project will deploy its token on Mantle Network, launch a liquidity pool, and integrate its strategy-building engine directly into Mantle’s ecosystem. This expansion brings a new class of AI-managed trading activity on-chain and gives Almanak users access to Mantle’s fast, low-cost execution environment for algorithmic code-based strategies.

Together, Bybit, Mantle, and Almanak are establishing a seamless liquidity loop where AI-powered strategies can operate across centralized and decentralized venues, providing users with greater accessibility, transparency, and execution efficiency.

Unlocking a New Era of AI-Powered Onchain Capital Efficiency

Almanak enables users to build, research, test, and deploy sophisticated quantitative strategies using a swarm of specialized AI agents—all without writing code. Integrating with Mantle Network unlocks a high-performance execution layer where these agents can operate with precision, enabling high-frequency rebalancing, automated multi-step strategies, and complex simulations that are impractical on high-cost chains.

Mantle’s low-fee, high-throughput architecture provides the ideal substrate for these workflows, supporting advanced automation and composable strategy design across the ecosystem.

Bybit complements this with global exchange infrastructure acting as the Liquidity Bridge, enabling capital to flow seamlessly between Almanak’s AI-powered strategies, Mantle’s on-chain environment, and broader market venues. More than 70 million users will gain streamlined access to both AI-managed strategy execution and Mantle-native liquidity.

As part of the rollout, Almanak will launch a two-sided liquidity pool on Mantle to deepen capital availability and support the growth of composable, AI-driven assets across the network.

“Almanak brings a new dimension of intelligent liquidity to Mantle,” said Emily Bao, Key Advisor at Mantle and Head of Spot at Bybit. “By combining AI-driven strategy creation with Mantle’s high-speed execution layer and Bybit’s global liquidity, we’re unlocking an integrated financial environment where sophisticated automation becomes accessible to users and institutions worldwide.”

“Deploying AI strategies on Mantle gives our users the high-performance environment required for today’s models,” said Neo, CEO of Almanak. “Low-cost, scalable infrastructure enables more complex simulation, faster iteration, and more efficient execution. Mantle amplifies what AI-powered DeFi can achieve.”

Advancing the Future of AI-Driven Onchain Finance

The collaboration marks a major step toward scaling AI-driven finance across both CeFi and DeFi. By merging Almanak’s AI strategy engine, Mantle’s execution infrastructure, and Bybit’s global distribution, the partnership establishes a unified framework for deploying quantitative strategies in a frictionless, intelligent, liquid, multi-chain environment.

This foundation unlocks new opportunities for traders, institutions, and developers while strengthening Mantle’s position as a leading chain for algorithmic, automated, and AI-native DeFi innovation.

About Mantle

Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with on-chain liquidity and access real-world assets, powering how real-world finance flows.

With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network’s partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, OP-Succinct and EigenLayer.

For more information about Mantle, please visit: mantle.xyz
For more social updates, please follow: Mantle Official X & Mantle Community Channel 
For media enquiries, please contact: contact@mantle.xyz 

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open, and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

About Almanak

Almanak is the largest DeFAI protocol and is more than twice the size of the rest of the category combined. It is an AI native asset management platform where a team of specialized agents known as the AI Swarm builds, tests, and simulates advanced code based strategies that are ready to be deployed by users. The AI Swarm creates strategy logic and produces deployable code, but it does not manage funds directly. Strategies run entirely on code, ensuring predictable and transparent execution.

Users can deploy strategies for their own use or publish them in vaults for others to participate in, allowing strategy creators to scale their impact and monetize their work. This model combines the creativity and speed of AI generated strategy development with user control and code driven execution, establishing Almanak as the leading platform for AI powered on chain asset management.

Discover the power of the AI Swarm at https://builder.almanak.co/

Website | X | Discord | Telegram

Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006

By
Advertorial Desk
-

HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”) and Formation Bio today announced Formation Bio’s acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation Bio’s newly formed subsidiary Bleecker Bio.

LNK01006 recently received IND clearance from the FDA to initiate first-in-human studies in the US. Formation Bio plans to initiate a Phase 1 study in the first half of 2026, reflecting the company’s growing momentum in building a diverse portfolio of high-potential, clinical-stage assets.

LNK01006 is a next-generation, CNS-penetrant allosteric TYK2 inhibitor that combines potent, selective inhibition of TYK2-mediated cytokine signaling with a pharmacologic profile optimized for central immune modulation. Its potential best-in-class selectivity and CNS exposure are designed to regulate immune signaling within the central nervous system, potentially modulating the immune responses implicated in a range of autoimmune and inflammatory diseases. Its unique pharmacologic profile offers optionality to explore indications where central or compartmentalized immune pathways are believed to play a key role.

“This asset represents a prime example of what we call our ‘Known In New’ strategy of applying validated mechanisms to novel areas of high unmet need,” said David Steinberg, Chief Business Officer at Formation Bio. “Leveraging world class human expertise, robust clinical data sets, and homegrown, state-of the-art AI tools, we’ve developed deeply grounded hypotheses around novel therapeutic applications of clinically derisked asset classes.”

Founded by veteran drug hunters from Johnson & Johnson, Merck, and Pfizer, Lynk Pharmaceuticals has established a broad discovery platform in immunology and inflammation. LNK01006 reflects Lynk Pharmaceuticals’ medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration.

“We are excited to partner with Formation Bio to advance LNK01006 into the clinic,” said Zhao-Kui (ZK) Wan, CEO of Lynk Pharmaceuticals. “Formation Bio’s experienced clinical development team and AI-enabled capabilities provide the ideal environment to translate this compound’s scientific potential into meaningful patient impact.”

Under the terms of the agreement, Lynk Pharmaceuticals will receive a minority equity stake in Bleecker Bio, an upfront payment and additional development, regulatory, and commercial milestones totaling up to $605 million US dollars and tiered royalties on potential future sales. Pacific Bridge NY, a New York-based investment fund specializing in supporting companies through late preclinical and clinical development, is a minority co-investor in Bleecker Bio.

Formation Bio acquires and advances high-potential assets, bringing the capital, technology, and development infrastructure needed to move promising programs forward in-house. Its model combines deep therapeutic expertise, dedicated operating teams, and a proprietary AI platform that streamlines everything from asset sourcing to clinical execution – with the ultimate goal of improving development speed, efficiency, and probability of success.

About Formation Bio

Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. Formation Bio has built technology and AI platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging their proprietary tech and AI capabilities, ultimately helping to bring new medicines to patients.

About Lynk Pharmaceuticals

Lynk Pharmaceuticals is a clinical stage company dedicated to discovering and developing novel medicines to treat immunology and inflammatory diseases. Lynk Pharmaceuticals was founded by veteran drug hunters from Pfizer, Merck and Johnson & Johnson with collectively more than several decades of rich experiences in drug discovery. Driven by a higher purpose, Lynk aims at growing into a market leader for developing innovative therapies to address unmet medical needs.

About Pacific Bridge NY

Pacific Bridge NY (PBNY) is a cross-border venture capital fund investing in emerging biotech programs with strong scientific foundations and significant global development potential. The firm partners closely with management teams, contributing to the shaping of preclinical and clinical development strategies to help accelerate advancement across key stages of growth.

1...1,5131,5141,515...6,441Page 1,514 of 6,441